NASDAQ · VTYX
Healthcare · Biotechnology
$14.00
Up+$0.00 (+0.00%)
Updated Aug 15, 2026, 2:29 AM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
VTYX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning VTYX.
VTYX research
Company profile and research snapshot.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 8, 2026 | Oppenheimer | Perform | — |
| Jan 8, 2026 | Wells Fargo | Equal-Weight | — |
| Jan 8, 2026 | LifeSci Capital | Market Perform | — |
| Jan 8, 2026 | HC Wainwright & Co. | Neutral | — |
| Jan 8, 2026 | UBS | Neutral | — |
No generated briefing is available yet.
Yahoo · Feb 14, 2026
Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy.
Yahoo · Feb 14, 2026
This clinical-stage biotech develops monoclonal antibody therapies targeting chronic inflammatory and immunological diseases.
Yahoo · Jan 7, 2026
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.3% in the morning session after the company announced a partnership to develop a new oral obesity drug and was reported to be in advanced talks to acquire Ventyx Biosciences for over $1 billion.
Yahoo · Jan 7, 2026
US equity futures were flat ahead of Wednesday's opening bell as traders digested labor market data.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VTYX.
